Pharmacyclics (PCYC) Tops Q4 EPS by 20c

Pharmacyclics (NASDAQ: PCYC) reported Q4 EPS of $0.96, $0.20 better than the analyst estimate of $0.76. Revenue for the quarter came in at $290 million versus the consensus estimate of $267.5 million.

Worldwide Collaboration and License Agreement with Janssen

Under the Agreement, the repayment of Excess Amounts is contingent and would become payable, with interest, to Janssen from the Company's quarterly share of pre-tax commercial profits, commencing after the third profitable quarter for the collaboration until the total Excess Amounts have been repaid from the Company's earned pre-tax collaboration net profit in subsequent quarters. As of December 31, 2014, total Excess Amounts were $138 million which was comprised of the cumulative amount funded by Janssen to-date of $134 million and interest of $4 million.

For earnings history and earnings-related data on Pharmacyclics (PCYC) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Lynx Equity sees Micron and SanDisk breakout as volatility normalizes
• TSX movers: VersaBank jumps 10% as corporate catalysts lift top gainers